| Our previous study showed that miR-1826 was a newly identified oncogenic non-coding RNA in colorectal cancer(CRC).But the potential relationship between miR-1826 and tumor metastasis has not been fully elucidated.The purpose of this study was to evaluate the clinical significance of circulating miR1826 and its possible associations with CTCs in CRC.Our results firstly found that serum miR-1826 was significantly up-regulated in CRC patients,compared with that in healthy volunteers(p=0.003).Similar results were also found in mCRC(p=0.001)and ACRC(p<0.001)patients respectively.Clinicopathological analysis implied that circulating miR-1826 was positively associated with pT stage(p=0.026),lymphatic metastasis(p=0.034),distant metastasis(p=0.012)and TNM stage(p=0.020).Besides,our univariate and multivariate analyses demonstrated that high serum miR-1826 expression could act as a prognostic and independent factor for OS of CRC patients(p<0.05),which led to a poorer 5-year OS rate(p=0.025).The AUC value of circulating miR-1826 was up to 0.848 ± 0.043,which strongly suggested serum miR-1826 as an effective diagnostic biomarker in CRC patients(p<0.001).Our subsequent experiments demonstrated that patients with high level of CTCs showed a higher level of miR-1826 expression,compared with the CTCs negative patients(p=0.011).Similar results also showed that the amount of CTCs in high miR-1826 group was significantly higher than that in low miR-1826 group(p=0.001).Furthermore,the relationship between serum miR-1826 and CTCs was analyzed using SPSS software and a significant logarithmic relationship was found,which meant that circulating miR-1826 closely correlated with the amount of CTCs in CRC patient serum(r=0.283,p<0.01).Our findings strongly suggested that serum miR-1826 could serve as an effective and non-invasive biomarker for diagnosis and prognosis of CRC.Circulating miR-1826 may be an important target in CRC therapy. |
PDF Full Text Request